10月13日，南方港股医药行业混合发布2026年第三季度报告，成为公募基金行业首份三季报。报告显示，该基金A、C份额季内净值增长率分别达到18.49%、17.73%，并对创新药及CXO板块的持仓结构进行了明显调整。 这份季报的亮相，与三季度医药板块的整体走强形成呼应。医药主题基金从上半年的“陪跑”角色迅速切换为“领跑者”，近三个月主动权益基金涨幅前15名全部被医药主题基金占据。 降仓位、加...
Source Link10月13日，南方港股医药行业混合发布2026年第三季度报告，成为公募基金行业首份三季报。报告显示，该基金A、C份额季内净值增长率分别达到18.49%、17.73%，并对创新药及CXO板块的持仓结构进行了明显调整。 这份季报的亮相，与三季度医药板块的整体走强形成呼应。医药主题基金从上半年的“陪跑”角色迅速切换为“领跑者”，近三个月主动权益基金涨幅前15名全部被医药主题基金占据。 降仓位、加...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.